Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 7—July 2019
Synopsis

Added Value of Comprehensive Program to Provide Universal Access to Care for Sputum Smear–Negative Drug-Resistant Tuberculosis, China

Fei Huang, Susan van den Hof, Yan Qu, You Li, Hui ZhangComments to Author , Lixia Wang, Miaomiao Sun, Wei Lu, Shuangyi Hou, Tianhua Zhang, Shitong Huan, Daniel P. Chin, and Frank Cobelens
Author affiliations: Chinese Center for Disease Control and Prevention, Beijing, China (F. Huang, Y. Qu, Y. Li, H. Zhang, L. Wang); The Royal Netherlands Tuberculosis Foundation, The Hague, the Netherlands (S. van den Hof); Academic Medical Center, Amsterdam, the Netherlands (S. van den Hof, F. Cobelens); PATH, Beijing (M. Sun); Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China (W. Lu); Hubei Provincial Center for Disease Control and Prevention, Hubei, China (S. Hou); Shaanxi Provincial Institute for Tuberculosis Control and Prevention, Shaanxi, China (T. Zhang); Bill & Melinda Gates Foundation, Beijing (S. Huan); Bill & Melinda Gates Foundation, Seattle, Washington, USA (D.P. Chin)

Main Article

Table 4

Smear results for patients who did and who did not start SLD treatment and outcomes for baseline and intervention periods in study of added value of comprehensive program to provide universal access to care for sputum smear–negative drug-resistant TB, China*

Characteristic Baseline, no. (%)
 Intervention, no. (%)
Smear-positive Smear-negative Smear-positive Smear-negative
Initiated SLD treatment 18 2 83 11
Cure 9 (50.0) 1 (50) 14 (16.9) 0
Treatment completion 1 (5.6) 1 (50) 27 (32.5) 6 (54.5)
Death 2 (11.1) 0 9 (10.8) 1 (9.1)
Treatment failure 3 (16.7) 0 5 (6.0)† 1 (9.1)
Lost to follow-up 0 0 6 (7.2) 0
Stop treatment because of side effects 0 0 8 (9.6) 0
Other
 3 (16.7)
 0
14 (16.9)
 3 (27.3)
Did not initiate SLD treatment 13 0 14 2 (18.2)
No regimen change, continued first-line treatment 11 (84.6)‡ 0 2 (14.3) 0
Death 1 (7.7) 0 4 (28.6) 0
Lost to follow-up 0 0 3 (21.4) 0
Treatment refusal because of nonfinancial reason 0 0 1 (7.1) 1 (50.0)
Other
 1 (7.7)
 0
4 (28.6)
 1 (50.0)
Total 31 2 97 13

*SLD, second-line drug; TB, tuberculosis.
†Includes 10 patients with TB resistant to rifampin but not isoniazid, who were not eligible for SLD treatment during the baseline period.
‡Includes 2 patients given treatment for extensively drug-resistant tuberculosis.

Main Article

Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external